IP Library Granted Patent US 10,717,737
Granted Patent B2
US 10,717,737 · App. 16/195,026 · Granted Jul 21, 2020

Cyclopropylamines as LSD1 inhibitors

Inventors: Liangxing Wu (Wilmington, DE); Chunhong He (Chadds Ford, PA); Wenqing Yao (Chadds Ford, PA); Fenglei Zhang (Berwyn, PA)
Assignee: Incyte Corporation
C07D471/10A61K31/397A61K31/435A61K31/445A61K31/4468A61K31/454A61K31/4523A61K31/497A61K31/506A61K45/06C07D205/04C07D211/14C07D211/16C07D211/32C07D211/34C07D211/58C07D401/06C07D401/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,717,737
App. No.
16/195,026
Granted
Jul 21, 2020
Kind
B2
Abstract

The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.

Claims (15)

1. A method of treating cancer, wherein said cancer is selected from myelodysplasia syndrome, acute myelogenous leukemia, undifferentiated small cell lung cancer, Ewing's sarcoma, and primary myelofibrosis, comprising administering to a patient a therapeutically effective amount of a compound selected from:

1-{[4-(methoxymethyl)-4-({[(1R,2 S)-2-phenylcyclopropyl]amino}methyl)piperidin-1-yl]methyl}cyclopentanecarboxylic acid,

1-{[4-(methoxymethyl)-4-({[(1R,2 S)-2-phenylcyclopropyl]amino}methyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid,

1-{[4-({[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino}methyl)-4-(methoxymethyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid, and

1-{[4-(ethoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid,

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the cancer is myelodysplasia syndrome.

3. The method of claim 1 , wherein the cancer is acute myelogenous leukemia.

4. The method of claim 1 , wherein the cancer is Ewing's sarcoma.

5. The method of claim 1 , wherein the cancer is undifferentiated small cell lung cancer.

6. The method of claim 1 , wherein the cancer is primary myelofibrosis.

7. The method of claim 1 , wherein the compound is 1-{[4-(methoxymethyl)-4-({[(1R,2 S)-2-phenylcyclopropyl]amino}methyl)piperidin-1-yl]methyl}cyclopentanecarboxylic acid, or a pharmaceutically acceptable salt thereof.

8. The method of claim 1 , wherein the compound is 1-{[4-(methoxymethyl)-4-({[(1R,2 S)-2-phenylcyclopropyl]amino}methyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid, or a pharmaceutically acceptable salt thereof.

9. The method of claim 1 , wherein the compound is 1-{[4-({[(1R,2 S)-2-(4-fluorophenyl)cyclopropyl]amino}methyl)-4-(methoxymethyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid, or a pharmaceutically acceptable salt thereof.

10. The method of claim 1 , wherein the compound is 1-{[4-(ethoxymethyl)-4-({[(1R,2 S)-2-phenylcyclopropyl]amino}methyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid, or a pharmaceutically acceptable salt thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2021
From: INCYTE CORPORATION
To: INCYTE CORPORATION; INCYTE HOLDINGS CORPORATION
Reel/Frame 058815/0857 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2019
From: WU, LIANGXING; COURTER, JOEL R.; HE, CHUNHONG; QIAN, DING-QUAN; SHEN, BO; WANG, XIAOZHAO; YAO, WENQING; ZHANG, FENGLEI
To: INCYTE CORPORATION
Reel/Frame 048157/0582 →